Respondents	No. of Respondents	No. of responses/ respondent	Avg. burden/ responses (in hrs.)	Total burden (in hrs.)
Households	2667	7	.369	4908

Dated: November 29, 1995.

Wilma G. Johnson,

Acting Associate Director for Policy Planning And Evaluation, Centers for Disease Control and Prevention (CDC).

[FR Doc. 95–29558 Filed 12–4–95; 8:45 am]

BILLING CODE 4163–18–P

Food and Drug Administration

[Docket No. 95N–0358]

Revised FDA Form 2830 Blood Establishment Registration and Product Listing (8/95); Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the availability of the revised FDA Form 2830 Blood Establishment Registration and Product Listing (8/95). This form replaces the previous edition of FDA Form 2830 (7/93). FDA Form 2830 is used for blood establishment registration and product listing, in accordance with the agency's regulations. FDA has made minor changes to the blood establishment registration and product listing which are intended to update the form, simplify processing, provide for efficient and effective use of the data base, and decrease expenditure of resources for both FDA and industry.

DATES: FDA will continue to accept submissions using the previous FDA Form 2830 (7/93) until June 5, 1996.

FOR FURTHER INFORMATION CONTACT: Valerie A. Windsor, Center for Biologics Evaluation and Research (HFM–630), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852–1448, 301–594–3074.

ADDRESSES: Submit written requests for single copies of the revised FDA Form 2830 Blood Establishment Registration and Product Listing (8/95) to the Congressional and Consumer Affairs Branch (HFM–12), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852–1448, or call FDA's automated information system at 800–835–4709. Send two self-addressed adhesive labels to assist that office in processing your requests. The revised FDA Form 2830 Blood Establishment Registration and Product Listing (8/95) may also be obtained by calling the CBER FAX Information System (FAX—ON—DEMAND) at 301–594–1939 from a touch tone phone. Submit written comments on the revised FDA Form 2830 Blood Establishment Registration and Product Listing (8/95) to the Dockets Management Branch (HFA–305), Food and Drug Administration, rm. 1–23, 12420 Parklawn Dr., Rockville, MD 20857. Two copies of any comments are to be submitted, except that individuals may submit one copy. Requests and comments should be identified with the docket number found in brackets in the heading of this document. The revised FDA Form 2830 Blood Establishment Registration and Product Listing (8/95) and received comments are available for public examination in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.

SUPPLEMENTARY INFORMATION: FDA is making available revised FDA Form 2830 Blood Establishment Registration and Product Listing (8/95), used in accordance with part 607 (21 CFR part 607), by owners or operators of establishments that engage in the manufacturing of blood products. Minor revisions have been made to the format of the form and the information solicited which include, but are not limited to, the following: (1) Revised FDA Form 2830 was reformatted into a single copy form, which replaces the previous four-copy form; (2) item 15, products, was revised by: (a) Adding Red Blood Cells Rejuvenated Frozen and Red Blood Cells Rejuvenated Deglycerolized and (b) adding a column to identify irradiated blood products; (3) item 13, type establishment, was revised by adding product testing laboratory, with the subheadings: Independent and associated with community or hospital blood bank; and (4) instructions for completing blood registration FDA Form 2830, were revised and included on a separate page.

In addition, the revised form continues to solicit the following information: (1) Registration number; (2) legal name and location; (3) reporting official; (4) type of ownership; (5) type establishment; (6) listing of products collected, processed, prepared, tested, and stored for distribution; and (7) human immunodeficiency virus (HIV) and hepatitis B surface antigen (HBsAg) proficiency test program name.

In accordance with § 607.20, owners or operators of all establishments that engage in the manufacture of blood products are required to register and to submit a list of every blood product in commercial distribution, whether or not the output of such blood product establishment or any particular blood product so listed enters interstate commerce.

Owners or operators of establishments that engage in the manufacturing of blood products that are currently registered with FDA need not request the revised form. In accordance with § 607.22, FDA Form 2830 will be distributed by FDA before November 15 of each year to establishments whose product registration for that year was validated, pursuant to § 607.35. In addition, these establishments are required to update their blood product listing information every June and December. New owners or operators of establishments that engage in the manufacturing of blood products may request the revised form as instructed under the **ADDRESSES** caption (see above).

Owners or operators of establishments that engage in the manufacturing of blood products that are preparing to submit applications for blood establishment registration and product listing should now utilize the revised FDA Form 2830 (8/95). FDA will continue to accept submissions using the previous FDA Form 2830 (7/93) until June 5, 1996.

Under the Paperwork Reduction Act of 1995 (Pub. L. 104–13), all forms requesting a collection of information on identical items from 10 or more public respondents must be approved by the Office of Management and Budget (OMB) and must display a valid OMB control number and expiration date. OMB approval for FDA Form 2830 was obtained on February 9, 1993, and given OMB approval number 0910–0052; expiration date February 28, 1996, however, the expiration date has been extended by OMB to May 31, 1996. Since these minor revisions to FDA Form 2830 did not increase burden to the public, OMB approval was not required.

Dated: November 28, 1995.

William B. Schultz,

Deputy Commissioner for Policy.

[FR Doc. 95–29479 Filed 12–4–95; 8:45 am]

BILLING CODE 4160–01–F

Request for Nominations for Members on Public Advisory Committees; Science Board to the Food and Drug Administration

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is requesting nominations for members to serve on the Science Board to the Food and Drug Administration (the board). Nominations will be accepted for current vacancies and vacancies that will or may occur on the board during the next 24 months.

FDA has a special interest in ensuring that women, minority groups, and individuals with disabilities are adequately represented on advisory committees, and therefore, extends particular encouragement to nominations for appropriately qualified female, minority, or physically disabled candidates. Final selections from among qualified candidates for each vacancy will be determined by the expertise required to meet specific agency needs and in a manner to ensure appropriate balance of membership.

DATES: Nominations should be received by January 15, 1996.

ADDRESSES: All nominations and curricula vitae from academia, industry, and government representatives, except for general public representatives (consumer-nominated members), should be sent to Zelma S. Rein (address below). All nominations for general public representatives (consumer-nominated members) should be sent to Annette J. Funn (address below).

FOR FURTHER INFORMATION CONTACT:

Regarding all nominations for membership, except for general public representatives: Zelma S. Rein, Office of Science (HF–33), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–3340.

Regarding all nominations for general public representatives: Annette Funn, Office of Consumer Affairs, (HFE–50), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–443–5006.

SUPPLEMENTARY INFORMATION: FDA is requesting nominations for members to serve on the board for two vacancies occurring December 31, 1995, and four vacancies occurring December 31, 1996.

Function

The function of the board is to provide advice primarily to the agency's Senior Science Advisor and, as needed, to the Commissioner of Food and Drugs and other appropriate officials on specific complex and technical issues as well as emerging issues within the scientific community in academia and industry. Additionally, the board provides advice to the agency on keeping pace with technical and scientific evolutions in the field of regulatory science, on formulating an appropriate research agenda and on upgrading its scientific and research facilities to keep pace with these changes. The board also provides the means for critical review of agency-sponsored intramural and extramural scientific research programs.

Criteria for Members

Persons nominated for membership from academia, industry, and government representatives shall be knowledgeable in the fields of chemistry, pharmacology, toxicology, clinical research, and other scientific disciplines. The term of office is up to 4 years, depending on the appointment date.

General Public Representatives (Consumer-nominated Members)

FDA currently attempts to place members on advisory committees who are nominated by consumer organizations. These members are recommended by a consortium of 12 consumer organizations that has the responsibility for screening, interviewing, and recommending consumer-nominated candidates with appropriate scientific credentials. Candidates are sought who are aware of the consumer impact of committee issues, but who also possess enough technical background to understand and contribute to the committee's work. The agency notes, however, that for some advisory committees, it may require such nominees to meet the same technical qualifications and specialized training required of other expert members of the committee. The term of office for these members is up to 4 years, depending on the appointment date. Nominations are invited for consideration for membership as openings become available.

Nomination Procedures

Any interested person may nominate one or more qualified person for membership on the board. Nominations shall state that the nominee is aware of the nomination, is willing to serve as a member of the board, and appears to have no conflict of interest that would preclude board membership. Potential candidates will be asked by FDA to provide detailed information concerning such matters as financial holdings, consultancies, and research grants or contracts in order to permit evaluation of possible sources of conflict of interest.

This notice is issued under the Federal Advisory Committee Act (5 U.S.C. app. 2) and 21 CFR part 14, relating to advisory committees.

Dated: November 27, 1995.

Michael A. Friedman,

Deputy Commissioner for Operations.

[FR Doc. 95–29572 Filed 12–4–95; 8:45 am]

BILLING CODE 4160–01–F

Health Resources and Services Administration

Request for Nominations to the National Advisory Committee on Rural Health

AGENCY: Health Resources and Services Administration, HHS.

ACTION: Notice.

SUMMARY: The Health Resources and Services Administration (HRSA) is requesting nominations to fill five vacancies on the Secretary's National Advisory Committee on Rural Health.

DATES: Nominations must be received by close-of-business on Friday, January 5, 1996.

ADDRESSES: Nominations and the curricula vitae of nominees should be sent to Dena S. Puskin, Sc.D., Executive Secretary to the National Advisory Committee on Rural Health, Room 9–05, 5600 Fishers Lane, Rockville, Maryland 20857.

FOR FURTHER INFORMATION CONTACT: Lisa Shelton at the above address, or phone (301) 443–0835 for further information.

SUPPLEMENTARY INFORMATION: The HRSA is requesting nominations under the authorities that established the National Advisory Committee on Rural Health: the Federal Advisory Committee Act of October 6, 1972 (Pub. L. 92–473) and Section 22 of the Public Health Service Act.

The National Advisory Committee on Rural Health is an 18-member citizens' panel appointed by the U.S. Secretary of Health and Human Services to provide advice on rural health needs. Drawing from committee members' diverse experience with rural health care issues,